Articles
US-UK pharma agreement finalised putting UK pharma ahead of others
08 Apr 2026The terms of the US-UK pharma agreement have been finalised, confirming that UK pharma will have 0% tariffs on medicines exported to the US.
Top tips from 2025 lessons when negotiating commercial contracts
26 Feb 2026Since I started my training contract in 1997 and for the nearly 30 years since, I have picked up a lot of learning points from my time drafting and negotiating commercial contracts and advising clients. As well as keeping up to date with new cases through the year, at the beginning of the year VWV lawyers have a commercial contract update training which provides an opportunity for us to stand back and question why we do things and what lessons we can learn from recent developments. This article shares some of those 2025 lessons with you.
MHRA inspections: what to expect and how to prepare
26 Feb 2026We understand that inspections can be daunting, and that it can be difficult to know how to deal with any deficiencies or unexpected issues that are identified. We share some practical tips on how to prepare for inspections and the steps to take post-inspection.
Supporting innovation, increasing transparency and prioritising efficiency - what to expect from the UK's new clinical trials regulatory framework
29 Jan 2026In its recent press release, the Medicines and Healthcare products Regulatory Agency (MHRA) reported a sharp increase in clinical trial activity in 2025. The UK regulator hopes this growth will continue into 2026 as reforms are brought in to speed-up and scale-up innovative research in support of the government's Life Sciences Sector Plan. We discuss what to expect from the new regulatory framework.
MHRA pro-innovation vision points to bright life sciences future for UK
29 Jan 2026After a challenging decade, the Medicines and Healthcare products Regulatory Agency (MHRA) has more than turned the corner and is ready to lead the world, for the good of UK life sciences and patients.
Subject access requests: key issues for the pharmaceuticals and life sciences sector
05 Jan 2026Subject access requests (SARs) continue to pose significant challenges for organisations in the pharmaceuticals and life sciences sector. They are often time-consuming, resource-intensive and frequently linked to wider complaints or disputes. This article shares some practical tips to help organisations manage SARs effectively.
